Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Documentation of long-term data regarding ticagrelor use and evaluation of reasons for discontinuation of ticagrelor in patients with ACS

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study

NCT02402400

Acute Coronary Syndromes Non ST Elevation Myocardial Infarction

COMPLETED PHASE4

The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

NCT02658838

LOVASTATIN/TICAGRELOR [VA Drug Interaction]

UNKNOWN PHASE4

Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI

NCT03315650

Non-valvular Atrial Fibrillation Acute Coronary Syndrome Percutaneous Coronary Intervention +1 more

COMPLETED

Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

NCT02725099

Acute Coronary Syndromes ST Elevation Myocardial Infarction

COMPLETED PHASE4

Ticagrelor in Remote Ischemic Preconditioning Study

NCT04174261

Periprocedural Myocardial Infarction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

REAL-TICA is a retrospective non-interventional study to assess the long-term use of ticagrelor in patients with ACS and to evaluate the reasons for discontinuation of ticagrelor.

For this purpose, selected sites from the ALKK-PCI registry and the respective patients will be identified. The sites' eligibility for this study includes the frequent use of ticagrelor during the acute phase of ACS. Eligible patients are characterised by the diagnosis of ACS and the use of ticagrelor during PCI.

The eligible sites will be contacted by IHF and asked to contact their eligible patients by letter to obtain informed consent of the patients for the planned 12M follow-up by IHF. A detailed questionnaire on events within the last 12 months, current symptoms, current medication and the use of ticagrelor will be added to the patients' letters. Patients then are asked to return their responses on consent to participate in the study as well as the filled in questionnaire to IHF. Alternatively, patients may choose to receive a telephone call by IHF to answer the detailed questionnaire in person. In case of essential information missing, IHF will contact the primary care physician of the patient directly to obtain information about clinical events and medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome (ACS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor

Treatment of ACS patients with Ticagrelor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anti-platelet therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18
* ACS (STEMI or NSTE-ACS) with PCI
* Ticagrelor treatment during the acute phase
* Written informed consent for participation in the study.